Ildong Holdings Co., Ltd. (KRX:000230)
South Korea · Delayed Price · Currency is KRW 5,690.00
+30.00 (0.53%)
Nov 2, 2026, 3:30 PM KST
Ildong Holdings Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 607,650 | 590,890 | 634,655 | 638,448 | 675,540 | 592,375 |
Revenue Growth | 0.05% | -6.90% | -0.59% | -5.49% | 14.04% | -0.69% |
Gross Profit Gross Profit Growth | 237,548 | 224,914 | 226,280 | 211,922 | 238,792 | 220,437 |
Operating Income Operating Income Growth | 24,155 | 12,145 | -4,664 | -79,553 | -98,263 | -81,732 |
Net Income Net Income Growth | 21,662 | 10,926 | 63,038 | -59,587 | -102,353 | -70,891 |
Earnings Per Share EPS Growth | 1896.03 | 966.78 | 4667.31 | -5277.00 | -9554.60 | -6278.00 |
EPS Growth | -55.88% | -79.29% | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Landlord Business Landlord Business Growth | 25,130 | 18,813 | 17,560 | 18,238 | 20,720 | 18,185 |
Cosmetic Surgery Medical Devices Manufacturing, Sales and Software Development Cosmetic Surgery Medical Devices Manufacturing, Sales and Software Development Growth | 18,444 | 17,754 | 27,994 | 22,908 | 3,038 | 2,586 |
Health Functionality Food Health Functionality Food Growth | - | 15,875 | 23,809 | 17,861 | 20,729 | 19,947 |
Advertising Agency Advertising Agency Growth | 5,939 | 5,038 | 4,670 | 6,877 | 8,217 | 9,883 |
Clinical Pharmacology Consulting Clinical Pharmacology Consulting Growth | 2,336 | 2,202 | 3,249 | 4,215 | 6,689 | 5,098 |
E-Commerce for Pharmaceuticals E-Commerce for Pharmaceuticals Growth | - | 10,789 | - | - | - | - |
Water Ionizer Water Ionizer Growth | - | 9,360 | 3,327 | 4,435 | 4,646 | 4,100 |
Medicines Manufacturing and Sales Medicines Manufacturing and Sales Growth | 581,368 | 565,967 | 614,941 | 600,758 | 637,714 | 560,132 |
Discontinued Discontinued Growth | - | -25,235 | -27,136 | - | - | - |
Cross-Sectoral Cross-Sectoral Growth | - | -29,673 | -33,765 | -37,621 | -39,634 | -38,410 |
Global New Drug Development Global New Drug Development Growth | - | - | 5.83 | - | - | - |
Total Total Growth | 620,034 | 590,890 | 634,655 | 638,448 | 675,540 | 592,375 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 80,446 | 77,815 | 94,566 | 102,480 | 136,414 | 200,835 |
Total Debt Total Debt Growth | 185,655 | 199,516 | 324,831 | 344,944 | 299,088 | 324,095 |
Net Cash (Debt) Net Cash Growth | -105,208 | -121,701 | -230,265 | -242,464 | -162,674 | -123,260 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -9208.55 | -10769.12 | -20391.71 | -21472.03 | -14278.56 | -10915.59 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 37,639 | 26,865 | 17,314 | -57,771 | -74,589 | -30,545 |
Capital Expenditures CapEx Growth | -12,769 | -14,036 | -10,971 | -13,487 | -12,698 | -17,153 |
Free Cash Flow Free Cash Flow Growth | 24,871 | 12,829 | 6,343 | -71,258 | -87,287 | -47,698 |
Free Cash Flow Growth | 186.78% | 102.26% | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 39.09% | 38.06% | 35.65% | 33.19% | 35.35% | 37.21% |
Operating Margin | 3.98% | 2.05% | -0.73% | -12.46% | -14.55% | -13.80% |
Pretax Margin | 8.80% | 5.13% | 8.40% | -20.69% | -25.60% | -29.80% |
Profit Margin | 3.56% | 1.85% | 9.93% | -9.33% | -15.15% | -11.97% |
FCF Margin | 4.09% | 2.17% | 1.00% | -11.16% | -12.92% | -8.05% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 100.000 | 100.000 | - | - | - | 100.000 |
Dividend Per Share Growth | 0% | - | - | - | - | - |
Dividend Yield | 1.76% | 0.77% | - | - | - | 0.68% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 3.00 | 13.74 | 1.46 | - | - | - |
P/FCF Ratio | 2.64 | 11.70 | 14.49 | - | - | - |
PS Ratio | 0.11 | 0.25 | 0.14 | 0.19 | 0.34 | 0.28 |